JUBILANT PHARMOVA
|
JUBILANT PHARMOVA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -3.83 | 26.01 | 52.51 | 56.39 | 36.07 |
| CEPS(Rs) | 30.75 | 49.93 | 57.98 | 63.89 | 59.52 |
| DPS(Rs) | 5.00 | 5.00 | 5.00 | 5.00 | 4.50 |
| Book NAV/Share(Rs) | 339.04 | 333.91 | 297.84 | 351.83 | 301.93 |
| Tax Rate(%) | 333.54 | 34.49 | 34.12 | 33.08 | 36.16 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.36 | 18.86 | 22.90 | 25.90 | 19.09 |
| EBIT Margin(%) | 3.44 | 12.66 | 17.30 | 20.29 | 12.33 |
| Pre Tax Margin(%) | 0.44 | 10.28 | 14.28 | 16.95 | 9.92 |
| PAT Margin (%) | -1.03 | 6.74 | 9.41 | 11.34 | 6.33 |
| Cash Profit Margin (%) | 7.79 | 12.96 | 15.13 | 17.03 | 10.40 |
| Performance Ratios | |||||
| ROA(%) | -0.63 | 4.44 | 5.45 | 5.74 | 5.55 |
| ROE(%) | -1.21 | 8.21 | 11.09 | 13.02 | 12.97 |
| ROCE(%) | 2.53 | 9.97 | 12.02 | 12.20 | 13.06 |
| Asset Turnover(x) | 0.61 | 0.66 | 0.58 | 0.51 | 0.88 |
| Sales/Fixed Asset(x) | 0.89 | 0.95 | 0.87 | 0.80 | 1.38 |
| Working Capital/Sales(x) | 3.16 | 3.20 | 3.20 | 2.47 | 3.65 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.13 | 1.05 | 1.15 | 1.25 | 0.72 |
| Receivable days | 54.89 | 52.04 | 63.24 | 78.33 | 48.12 |
| Inventory Days | 76.57 | 70.98 | 89.02 | 99.64 | 56.26 |
| Payable days | 134.99 | 133.47 | 191.38 | 264.67 | 111.74 |
| Valuation Parameters | |||||
| PER(x) | - | 14.91 | 12.96 | 4.41 | 18.42 |
| PCE(x) | 9.07 | 7.77 | 11.74 | 3.90 | 11.16 |
| Price/Book(x) | 0.82 | 1.16 | 2.28 | 0.71 | 2.20 |
| Yield(%) | 1.79 | 1.29 | 0.73 | 2.01 | 0.68 |
| EV/Net Sales(x) | 1.09 | 1.32 | 2.09 | 1.20 | 1.54 |
| EV/Core EBITDA(x) | 8.39 | 6.95 | 9.01 | 4.54 | 7.92 |
| EV/EBIT(x) | 31.65 | 10.46 | 12.08 | 5.93 | 12.50 |
| EV/CE(x) | 0.63 | 0.83 | 1.45 | 0.58 | 1.24 |
| M Cap / Sales | 0.71 | 1.01 | 1.78 | 0.66 | 1.16 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.47 | 0.52 | 2.05 | -34.41 | 21.19 |
| Core EBITDA Growth(%) | -30.24 | -17.43 | -10.80 | -10.67 | 13.88 |
| EBIT Growth(%) | -72.17 | -26.46 | -12.98 | 7.92 | -1.73 |
| PAT Growth(%) | -115.71 | -28.03 | -15.33 | 17.46 | -9.05 |
| EPS Growth(%) | -114.74 | -50.48 | -6.88 | 56.35 | -12.60 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.63 | 0.55 | 0.55 | 0.83 | 1.01 |
| Current Ratio(x) | 2.12 | 2.20 | 2.82 | 1.92 | 2.19 |
| Quick Ratio(x) | 1.34 | 1.42 | 1.74 | 1.22 | 1.52 |
| Interest Cover(x) | 1.15 | 5.33 | 5.73 | 6.07 | 5.11 |
| Total Debt/Mcap(x) | 0.77 | 0.47 | 0.24 | 1.17 | 0.46 |
Compare Financial Ratios of peers of JUBILANT PHARMOVA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| JUBILANT PHARMOVA | ₹10,843.6 Cr | -0.1% | 20.2% | 121.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
| CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics | |
JUBILANT PHARMOVA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | -0.1% |
20.2% |
121.8% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
